Clinical trial
A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell…
NCT00211068 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00211068 |
|---|---|
| Title | A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa |
| Official title | Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Pure Red-cell Aplasia |
| Intervention type | Drug |
| Interventions | No intervention |
| Enrollment | 124 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Apr 30, 2013 |
| Countries | Brazil, France, Norway, South Africa, Sweden, Thailand, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: